
    
      People treated with ranibizumab for edema due to retinal vein occlusion as part of previous
      studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist
      at the Wilmer Eye Institute are followed up to assess long term outcomes
    
  